Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial.
Petak I, Kamal M, Dirner A, Bieche I, Doczi R, Mariani O, Filotas P, Salomon A, Vodicska B, Servois V, Varkondi E, Gentien D, Tihanyi D, Tresca P, Lakatos D, Servant N, Deri J, du Rusquec P, Hegedus C, Bello Roufai D, Schwab R, Dupain C, Valyi-Nagy IT, Le Tourneau C. Petak I, et al. Among authors: servant n. NPJ Precis Oncol. 2021 Jun 23;5(1):59. doi: 10.1038/s41698-021-00191-2. NPJ Precis Oncol. 2021. PMID: 34162980 Free PMC article.
Dexrazoxane does not protect against doxorubicin-induced damage in young rats.
Héon S, Bernier M, Servant N, Dostanic S, Wang C, Kirby GM, Alpert L, Chalifour LE. Héon S, et al. Among authors: servant n. Am J Physiol Heart Circ Physiol. 2003 Aug;285(2):H499-506. doi: 10.1152/ajpheart.00047.2003. Epub 2003 Apr 24. Am J Physiol Heart Circ Physiol. 2003. PMID: 12714334 Free article.
Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial.
Le Tourneau C, Kamal M, Trédan O, Delord JP, Campone M, Goncalves A, Isambert N, Conroy T, Gentien D, Vincent-Salomon A, Pouliquen AL, Servant N, Stern MH, Le Corroller AG, Armanet S, Rio Frio T, Paoletti X. Le Tourneau C, et al. Among authors: servant n. Target Oncol. 2012 Dec;7(4):253-65. doi: 10.1007/s11523-012-0237-6. Epub 2012 Nov 17. Target Oncol. 2012. PMID: 23161020 Review.
Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial.
Le Tourneau C, Paoletti X, Servant N, Bièche I, Gentien D, Rio Frio T, Vincent-Salomon A, Servois V, Romejon J, Mariani O, Bernard V, Huppe P, Pierron G, Mulot F, Callens C, Wong J, Mauborgne C, Rouleau E, Reyes C, Henry E, Leroy Q, Gestraud P, La Rosa P, Escalup L, Mitry E, Trédan O, Delord JP, Campone M, Goncalves A, Isambert N, Gavoille C, Kamal M. Le Tourneau C, et al. Among authors: servant n. Br J Cancer. 2014 Jul 8;111(1):17-24. doi: 10.1038/bjc.2014.211. Epub 2014 Apr 24. Br J Cancer. 2014. PMID: 24762958 Free PMC article. Clinical Trial.
139 results